The application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer

References

1. Richards, DM, Hettinger, J, Feuerer, M. Monocytes and macrophages in cancer: development and functions. Cancer Microenviron 2013;6:179–91. https://doi.org/10.1007/s12307-012-0123-x.Search in Google Scholar

2. Lee, H-W, Choi, H-J, Ha, S-J, Lee, K-T, Kwon, Y-G. Recruitment of monocytes/macrophages in different tumor microenvironments. Biochim Biophys Acta Rev Canc 2013;1835:170–9. https://doi.org/10.1016/j.bbcan.2012.12.007.Search in Google Scholar

3. Anisiewicz, A, Okła, K, Wawruszak, A. Tumor associated macrophages-origin, characteristic and importance in breast cancer. Rev Res Cancer Treat 2015;1.Search in Google Scholar

4. Lin, A, Schildknecht, A, Nguyen, LT, Ohashi, PS. Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol Lett 2010;127:77–84. https://doi.org/10.1016/j.imlet.2009.09.003.Search in Google Scholar

5. Lutz, MB, Schuler, G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol 2002;23:445–9. https://doi.org/10.1016/s1471-4906(02)02281-0.Search in Google Scholar

6. Lutz, MB. Therapeutic potential of semi-mature dendritic cells for tolerance induction. Front Immunol 2012;3:123. https://doi.org/10.3389/fimmu.2012.00123.Search in Google Scholar

7. Dudek, AM, Martin, S, Garg, AD, Agostinis, P. Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity. Front Immunol 2013;4:438. https://doi.org/10.3389/fimmu.2013.00438.Search in Google Scholar

8. Lanzavecchia, A, Sallusto, F. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol 2001;13:291–8. https://doi.org/10.1016/s0952-7915(00)00218-1.Search in Google Scholar

9. Lijun, Z, Xin, Z, Danhua, S, Xiaoping, L, Jianliu, W, Huilan, W, .et al. Tumor-infiltrating dendritic cells may be used as clinicopathologic prognostic factors in endometrial carcinoma. Int J Gynecol Canc 2012;22:836–41. https://doi.org/10.1097/igc.0b013e31825401c6.Search in Google Scholar

10. Ma, Y, Shurin, GV, Peiyuan, Z, Shurin, MR. Dendritic cells in the cancer microenvironment. J Cancer 2013;4:36–44. https://doi.org/10.7150/jca.5046.Search in Google Scholar PubMed PubMed Central

11. Seliger, B. Different regulation of MHC Class i antigen processing components in human tumors. J Immunotoxicol 2008;5:361–7. https://doi.org/10.1080/15476910802482870.Search in Google Scholar PubMed

12. Gajewski, TF, Schreiber, H, Fu, YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014–22. https://doi.org/10.1038/ni.2703.Search in Google Scholar PubMed PubMed Central

13. Lardner, A. The effects of extracellular pH on immune function. J Leukoc Biol 2001;69:522–30.10.1189/jlb.69.4.522Search in Google Scholar

14. Lai, P, Rabinowich, H, Crowley-Nowick, PA, Bell, MC, Mantovani, G, Whiteside, TL. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Canc Res 1996;2:161–73. https://doi.org/10.1189/jlb.69.4.522.Search in Google Scholar

15. Elkabets, M, Ribeiro, VSG, Dinarello, CA, Ostrand-Rosenberg, S, Di Santo, JP, Apte, RN. IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 2010;40:3347–57. https://doi.org/10.1002/eji.201041037.Search in Google Scholar PubMed PubMed Central

16. Li, T, Yang, Y, Hua, X, Wang, G, Liu, W, Jia, C. Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Lett 2012;318:154–61. https://doi.org/10.1016/j.canlet.2011.12.020.Search in Google Scholar PubMed

17. Hoskin, D, Mader, J, Furlong, S, Conrad, D, Blay, J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol 2008;32:527–35. https://doi.org/10.3892/ijo.32.3.527.Search in Google Scholar

18. Ban, Y, Zhao, Y, Liu, F, Dong, B, Kong, B, Qu, X. Effect of indoleamine 2,3-dioxygenase expressed in HTR-8/SVneo cells on decidual NK cell cytotoxicity. Am J Reprod Immunol 2016;75:519–28. https://doi.org/10.1111/aji.12481.Search in Google Scholar PubMed

19. Lee, J-C, Lee, K-M, Kim, D-W, Heo, DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004;172:7335–40. https://doi.org/10.4049/jimmunol.172.12.7335.Search in Google Scholar PubMed

20. Slattery, K, Gardiner, CM. NK cell metabolism and TGFβ – implications for immunotherapy. Front Immunol 2019;10:2915. https://doi.org/10.3389/fimmu.2019.02915.Search in Google Scholar PubMed PubMed Central

21. Viel, S, Marçais, A, Guimaraes, FS-F, Loftus, R, Rabilloud, J, Grau, M. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal 2016;9:ra19. https://doi.org/10.1126/scisignal.aad1884.Search in Google Scholar PubMed

22. Chretien, AS, Le Roy, A, Vey, N, Prebet, T, Blaise, D, Fauriat, C. Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity. Front Immunol 2014;5. https://doi.org/10.3389/fimmu.2014.00122.Search in Google Scholar PubMed PubMed Central

23. Trotta, R, Dal Col, J, Yu, J, Ciarlariello, D, Thomas, B, Zhang, X, et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol 2008;181:3784–92. https://doi.org/10.4049/jimmunol.181.6.3784.Search in Google Scholar PubMed PubMed Central

24. Gao, Y, Souza-Fonseca-Guimaraes, F, Bald, T, Ng, SS, Young, A, Ngiow, SF, et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol 2017;18:1004–15. https://doi.org/10.1038/ni.3800.Search in Google Scholar PubMed

25. Cortez, VS, Ulland, TK, Cervantes-Barragan, L, Bando, JK, Robinette, ML, Wang, Q, et al. SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-β signaling. Nat Immunol 2017;18:995–1003. https://doi.org/10.1038/ni.3809.Search in Google Scholar PubMed PubMed Central

26. Tufa, DM, Ahmad, F, Chatterjee, D, Ahrenstorf, G, Schmidt, RE, Jacobs, R. IL-1β limits the extent of human 6-sulfo LacNAc dendritic cell (slanDC)-mediated NK cell activation and regulates CD95-induced apoptosis. Cell Mol Immunol 2017;14:976–85. https://doi.org/10.1038/cmi.2016.17.Search in Google Scholar PubMed PubMed Central

27. Robson, NC, Wei, H, McAlpine, T, Kirkpatrick, N, Cebon, J, Maraskovsky, E. Activin-A attenuates several human natural killer cell functions. Blood 2009;113:3218–25. https://doi.org/10.1182/blood-2008-07-166926.Search in Google Scholar PubMed

28. Groh, V, Wu, J, Yee, C, Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734–8. https://doi.org/10.1038/nature01112.Search in Google Scholar PubMed

29. Textor, S, Dürst, M, Jansen, L, Accardi, R, Tommasino, M, Trunk, MJ, et al. Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Canc 2008;123:2343–53. https://doi.org/10.1002/ijc.23733.Search in Google Scholar PubMed

30. Pesce, S, Tabellini, G, Cantoni, C, Patrizi, O, Coltrini, D, Rampinelli, F, et al. B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. OncoImmunology 2015;4. https://doi.org/10.1080/2162402x.2014.1001224.Search in Google Scholar PubMed PubMed Central

31. Movahedi, K, Laoui, D, Gysemans, C, Baeten, M, Stangé, G, Den Van Bossche, J, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010;70:5728–39. https://doi.org/10.1158/0008-5472.can-09-4672.Search in Google Scholar

32. MacDonald, KPA, Palmer, JS, Cronau, S, Seppanen, E, Olver, S, Raffelt, NC, et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 2010;116:3955–63. https://doi.org/10.1182/blood-2010-02-266296.Search in Google Scholar PubMed

33. Sica, A, Bronte, V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest Am Soc Clin Invest 2007;117:1155–66. https://doi.org/10.1172/jci31422.Search in Google Scholar

34. Hagemann, T, Biswas, SK, Lawrence, T, Sica, A, Lewis, CE. Regulation of macrophage function in tumors: the multifaceted role of NF-κB. Blood 2009;113:3139–46. https://doi.org/10.1182/blood-2008-12-172825.Search in Google Scholar PubMed PubMed Central

35. Mantovani, A, Marchesi, F, Malesci, A, Laghi, L, Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017;14:399–416. https://doi.org/10.1038/nrclinonc.2016.217.Search in Google Scholar PubMed PubMed Central

36. Allavena, P, Mantovani, A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 2012;167:195–205. https://doi.org/10.1111/j.1365-2249.2011.04515.x.Search in Google Scholar PubMed PubMed Central

37. De Palma, M, Lewis, CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013;23:277–86. https://doi.org/10.1016/j.ccr.2013.02.013.Search in Google Scholar PubMed

38. Menetrier-Caux, C, Montmain, G, Dieu, MC, Bain, C, Favrot, MC, Caux, C, et al. Inhibition of the differentiation of dendritic cells from CD34+ progenitors by tumor cells: role of interleukin-6 and macrophage colony- stimulating factor. Blood 1998;92:4778–91. https://doi.org/10.1182/blood.v92.12.4778.Search in Google Scholar

39. Bharadwaj, U, Li, M, Zhang, R, Chen, C, Yao, Q. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res 2007;67:5479–88. https://doi.org/10.1158/0008-5472.can-06-3963.Search in Google Scholar

40. Gabrilovich, DI, Chen, HL, Girgis, KR, Cunningham, HT, Meny, GM, Nadaf, S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096–103. https://doi.org/10.1038/nm1096-1096.Search in Google Scholar PubMed

41. Sombroek, CC, Stam, AGM, Masterson, AJ, Lougheed, SM, Schakel, MJAG, Meijer, CJLM, et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 2002;168:4333–43. https://doi.org/10.4049/jimmunol.168.9.4333.Search in Google Scholar PubMed

42. Stock, A, Booth, S, Cerundolo, V. Prostaglandin E2 suppresses the differentiation of retinoic acid-producing dendritic cells in mice and humans. J Exp Med 2011;208:761–73. https://doi.org/10.1084/jem.20101967.Search in Google Scholar PubMed PubMed Central

43. Liu, Y, Xiao, L, Joo, K Il, Hu, B, Fang, J, Wang, P. In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice. Biomacromolecules 2014;15:3836–45. https://doi.org/10.1021/bm501166j.Search in Google Scholar PubMed PubMed Central

44. López, MN, Pereda, C, Segal, G, Muñoz, L, Aguilera, R, González, FE, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor β-expressing T cells. J Clin Oncol 2009;27:945–52. https://doi.org/10.1200/jco.2008.18.0794.Search in Google Scholar

45. Hargadon, KM. Tumor-altered dendritic cell function: implications for anti-tumor immunity. Front Immunol 2013;4:192. https://doi.org/10.3389/fimmu.2013.00192.Search in Google Scholar PubMed PubMed Central

46. Galon, J, Costes, A, Sanchez-Cabo, F, Kirilovsky, A, Mlecnik, B, Lagorce-Pagès, C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960–4. https://doi.org/10.1126/science.1129139.Search in Google Scholar PubMed

47. Steidl, C, Lee, T, Shah, SP, Farinha, P, Han, G, Nayar, T, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 2010;362:875–85. https://doi.org/10.1056/nejmoa0905680.Search in Google Scholar

48. DeNardo, DG, Brennan, DJ, Rexhepaj, E, Ruffell, B, Shiao, SL, Madden, SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:54–67. https://doi.org/10.1158/2159-8274.cd-10-0028.Search in Google Scholar

49. Kurahara, H, Shinchi, H, Mataki, Y, Maemura, K, Noma, H, Kubo, F, et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 2011;167:e211–9. https://doi.org/10.1016/j.jss.2009.05.026.Search in Google Scholar PubMed

50. Zhang, BC, Gao, J, Wang, J, Rao, ZG, Wang, BC, Gao, JF. Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med Oncol 2011;28:1447–52. https://doi.org/10.1007/s12032-010-9638-5.Search in Google Scholar PubMed

51. Curiel, TJ, Wei, S, Dong, H, Alvarez, X, Cheng, P, Mottram, P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562–7. https://doi.org/10.1038/nm863.Search in Google Scholar PubMed

52. Krempski, J, Karyampudi, L, Behrens, MD, Erskine, CL, Hartmann, L, Dong, H, et al. Tumor-infiltrating programmed death receptor-1 + dendritic cells mediate immune suppression in ovarian cancer. J Immunol 2011;186:6905–13. https://doi.org/10.4049/jimmunol.1100274.Search in Google Scholar PubMed PubMed Central

53. Ma, Y, Shurin, G V., Gutkin, DW, Shurin, MR. Tumor associated regulatory dendritic cells. Semin Cancer Biol 2012;22:298–306. https://doi.org/10.1016/j.semcancer.2012.02.010.Search in Google Scholar PubMed PubMed Central

54. Freund-Brown, J, Chirino, L, Kambayashi, T. Strategies to enhance NK cell function for the treatment of tumors and infections. Crit Rev Immunol 2018;38:105–30. https://doi.org/10.1615/critrevimmunol.2018025248.Search in Google Scholar PubMed PubMed Central

55. Li, Y, Sun, R, Li, Y, Sun, R. Tumor immunotherapy: new aspects of natural killer cells. Chinese J Cancer Res 2018;30:173–96. https://doi.org/10.21147/j.issn.1000-9604.2018.02.02.Search in Google Scholar PubMed PubMed Central

56. Ruggeri, L, Capanni, M, Casucci, M, Volpi, I, Tosti, A, Perruccio, K, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999;94:333–9. https://doi.org/10.1182/blood.v94.1.333.413a31_333_339.Search in Google Scholar

57. Guillerey, C, Huntington, ND, Smyth, MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol 2016;17:1025–36. https://doi.org/10.1038/ni.3518.Search in Google Scholar PubMed

58. Romagné, F, André, P, Spee, P, Zahn, S, Anfossi, N, Gauthier, L, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009;114:2667–77. https://doi.org/10.1182/blood-2009-02-206532.Search in Google Scholar PubMed PubMed Central

59. Benson, DM, Hofmeister, CC, Padmanabhan, S, Suvannasankha, A, Jagannath, S, Abonour, R, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012;120:4324–33. https://doi.org/10.1182/blood-2012-06-438028.Search in Google Scholar PubMed PubMed Central

60. Korde, N, Carlsten, M, Lee, MJ, Minter, A, Tan, E, Kwok, M, et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 2014;99. https://doi.org/10.3324/haematol.2013.103085.Search in Google Scholar PubMed PubMed Central

61. Benson, DM, Cohen, AD, Jagannath, S, Munshi, NC, Spitzer, G, Hofmeister, CC, et al. A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clin Canc Res 2015;21:4055–61. https://doi.org/10.1158/1078-0432.ccr-15-0304.Search in Google Scholar

62. Vey, N, Bourhis, JH, Boissel, N, Bordessoule, D, Prebet, T, Charbonnier, A, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012;120:4317–23. https://doi.org/10.1182/blood-2012-06-437558.Search in Google Scholar PubMed

63. Kohrt, HE, Thielens, A, Marabelle, A, Sagiv-Barfi, I, Sola, C, Chanuc, F, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2014;123:678–86. https://doi.org/10.1182/blood-2013-08-519199.Search in Google Scholar PubMed PubMed Central

64. Nijhof, IS, Lammerts van Bueren, JJ, van Kessel, B, Andre, P, Morel, Y, Lokhorst, HM, et al. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica 2015;100:263–8. https://doi.org/10.3324/haematol.2014.117531.Search in Google Scholar PubMed PubMed Central

65. Wieten, L, Mahaweni, NM, Voorter, CEM, Bos, GMJ, Tilanus, MGJ. Clinical and immunological significance of HLA-E in stem cell transplantation and cancer. Tissue Antigens 2014;84:523–35. https://doi.org/10.1111/tan.12478.Search in Google Scholar PubMed

66. Kochan, G, Escors, D, Breckpot, K, Guerrero-Setas, D. Role of non-classical MHC class I molecules in cancer immunosuppression. Oncoimmunology 2013;2. https://doi.org/10.4161/onci.26491.Search in Google Scholar PubMed PubMed Central

67. lo Monaco, E, Tremante, E, Cerboni, C, Melucci, E, Sibilio, L, Zingoni, A, et al. Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia 2011;13:822–30. https://doi.org/10.1593/neo.101684.Search in Google Scholar PubMed PubMed Central

68. Mamessier, E, Sylvain, A, Thibult, ML, Houvenaeghel, G, Jacquemier, J, Castellano, R, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011;121:3609–22. https://doi.org/10.1172/jci45816.Search in Google Scholar PubMed PubMed Central

69. André, P, Denis, C, Soulas, C, Bourbon-Caillet, C, Lopez, J, Arnoux, T, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 2018;175:1731–43.e13. https://doi.org/10.1016/j.cell.2018.10.014.Search in Google Scholar PubMed PubMed Central

70. van Montfoort, N, Borst, L, Korrer, MJ, Sluijter, M, Marijt, KA, Santegoets, SJ, et al. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell 2018;175:1744–55e15. https://doi.org/10.1016/j.cell.2018.10.028.Search in Google Scholar PubMed PubMed Central

71. Segal, NH, Naidoo, J, Curigliano, G, Patel, S, Sahebjam, S, Papadopoulos, KP, et al. First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer. J Clin Oncol 2018;36:3540. https://doi.org/10.1200/jco.2018.36.15_suppl.3540.Search in Google Scholar

72. Kamiya, T, Seow, SV, Wong, D, Robinson, M, Campana, D. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Invest 2019;129:2094–106. https://doi.org/10.1172/jci123955.Search in Google Scholar

73. González, Á, Rebmann, V, Lemaoult, J, Horn, PA, Carosella, ED, Alegre, E. The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci 2012;49:63–84. https://doi.org/10.3109/10408363.2012.677947.Search in Google Scholar PubMed

74. Heidenreich, S, Zu Eulenburg, C, Hildebrandt, Y, Stübig, T, Sierich, H, Badbaran, A, et al. Impact of the NK cell receptor LIR-1 (ILT-2/CD85j/LILRB1) on cytotoxicity against multiple myeloma. Clin Dev Immunol 2012. 2012. https://doi.org/10.1155/2012/652130.Search in Google Scholar PubMed PubMed Central

75. Ndhlovu, LC, Lopez-Vergès, S, Barbour, JD, Brad Jones, R, Jha, AR, Long, BR, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 2012;119:3734–43. https://doi.org/10.1182/blood-2011-11-392951.Search in Google Scholar PubMed PubMed Central

76. Gleason, MK, Lenvik, TR, McCullar, V, Felices, M, O’Brien, MS, Cooley, SA, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 2012;119:3064–72. https://doi.org/10.1182/blood-2011-06-360321.Search in Google Scholar PubMed PubMed Central

77. Da Silva, IP, Gallois, A, Jimenez-Baranda, S, Khan, S, Anderson, AC, Kuchroo, VK, et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res 2014;2:410–22. https://doi.org/10.1158/2326-6066.cir-13-0171.Search in Google Scholar

78. Wang, Z, Zhu, J, Gu, H, Yuan, Y, Zhang, B, Zhu, D, et al. The clinical significance of abnormal tim-3 expression on NK cells from patients with gastric cancer. Immunol Invest 2015;44:578–89. https://doi.org/10.3109/08820139.2015.1052145.Search in Google Scholar PubMed

79. Komita, H, Koido, S, Hayashi, K, Kan, S, Ito, M, Kamata, Y, et al. Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors. Oncol Rep 2015;34:2099–105. https://doi.org/10.3892/or.2015.4149.Search in Google Scholar PubMed

80. Xu, L, Huang, Y, Tan, L, Yu, W, Chen, D, Lu, C, et al. Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol 2015;29:635–41. https://doi.org/10.1016/j.intimp.2015.09.017.Search in Google Scholar PubMed

81. Zhu, C, Anderson, AC, Schubart, A, Xiong, H, Imitola, J, Khoury, SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005;6:1245–52. https://doi.org/10.1038/ni1271.Search in Google Scholar PubMed

82. Chiba, S, Baghdadi, M, Akiba, H, Yoshiyama, H, Kinoshita, I, Dosaka-Akita, H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012;13:832–42. https://doi.org/10.1038/ni.2376.Search in Google Scholar PubMed PubMed Central

83. DeKruyff, RH, Bu, X, Ballesteros, A, Santiago, C, Chim, Y-LE, Lee, H-H, et al. T cell/transmembrane, ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol 2010;184:1918–30. https://doi.org/10.4049/jimmunol.0903059.Search in Google Scholar PubMed PubMed Central

84. So, EC, Khaladj-Ghom, A, Ji, Y, Amin, J, Song, Y, Burch, E, et al. NK cell expression of Tim-3: first impressions matter. Immunobiology 2019;224:362–70. https://doi.org/10.1016/j.imbio.2019.03.001.Search in Google Scholar PubMed

85. Xu, L, Huang, Y, Tan, L, Yu, W, Chen, D, Lu, C, et al. Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol 2015;29:635–41. https://doi.org/10.1016/j.intimp.2015.09.017.Search in Google Scholar PubMed

86. Zhang, B, Zhao, W, Li, H, Chen, Y, Tian, H, Li, L, et al. Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155. Cancer Immunol Immunother 2016;65:305–14. https://doi.org/10.1007/s00262-016-1799-4.Search in Google Scholar PubMed

87. Stanietsky, N, Simic, H, Arapovic, J, Toporik, A, Levy, O, Novik, A, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA 2009;106:17858–63. https://doi.org/10.1073/pnas.0903474106.Search in Google Scholar PubMed PubMed Central

88. Stein, N, Tsukerman, P, Mandelboim, O. The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies. Hum Antibodies 2017;25:111–9. https://doi.org/10.3233/hab-160307.Search in Google Scholar PubMed

89. Xu, F, Sunderland, A, Zhou, Y, Schulick, RD, Edil, BH, Zhu, Y. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immunol Immunother 2017;66:1367–75. https://doi.org/10.1007/s00262-017-2031-x.Search in Google Scholar PubMed PubMed Central

90. Yu, X, Harden, K, Gonzalez, LC, Francesco, M, Chiang, E, Irving, B, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 2009;10:48–57. https://doi.org/10.1038/ni.1674.Search in Google Scholar PubMed

91. Roman Aguilera, A, Lutzky, VP, Mittal, D, Li, XY, Stannard, K, Takeda, K, et al. CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity. OncoImmunology 2018;7. https://doi.org/10.1080/2162402x.2018.1424677.Search in Google Scholar PubMed PubMed Central

92. Stojanovic, A, Fiegler, N, Brunner-Weinzierl, M, Cerwenka, A. CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-γ production in response to mature dendritic cells. J Immunol 2014;192:4184–91. https://doi.org/10.4049/jimmunol.1302091.Search in Google Scholar PubMed

93. Laurent, S, Queirolo, P, Boero, S, Salvi, S, Piccioli, P, Boccardo, S, et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med 2013;11:108. https://doi.org/10.1186/1479-5876-11-108.Search in Google Scholar

94. Benson, DM, Bakan, CE, Mishra, A, Hofmeister, CC, Efebera, Y, Becknell, B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010;116:2286–94. https://doi.org/10.1182/blood-2010-02-271874.Search in Google Scholar

95. Beldi-Ferchiou, A, Lambert, M, Dogniaux, S, Vély, F, Vivier, E, Olive, D, et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget 2016;7:72961–77. https://doi.org/10.18632/oncotarget.12150.Search in Google Scholar

96. Wiesmayr, S, Webber, SA, Macedo, C, Popescu, I, Smith, L, Luce, J, et al. Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD. Eur J Immunol 2012;42:541–50. https://doi.org/10.1002/eji.201141832.Search in Google Scholar

97. Pesce, S, Greppi, M, Tabellini, G, Rampinelli, F, Parolini, S, Olive, D, et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol 2017;139:335–46.e3. https://doi.org/10.1016/j.jaci.2016.04.025.Search in Google Scholar

98. Berger, R, Rotem-Yehudar, R, Slama, G, Landes, S, Kneller, A, Leiba, M, et al. Phase i safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Canc Res 2008;14:3044–51. https://doi.org/10.1158/1078-0432.ccr-07-4079.Search in Google Scholar

99. Chen, R, Zinzani, PL, Fanale, MA, Armand, P, Johnson, NA, Brice, P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin Lymphoma. J Clin Oncol 2017;35:2125–32. https://doi.org/10.1200/jco.2016.72.1316.Search in Google Scholar

100. Westin, JR, Chu, F, Zhang, M, Fayad, LE, Kwak, LW, Fowler, N, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014;15:69–77. https://doi.org/10.1016/s1470-2045(13)70551-5.Search in Google Scholar

101. Xu, F, Liu, J, Liu, D, Liu, B, Wang, M, Hu, Z, et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res 2014;74:3418–28. https://doi.org/10.1158/0008-5472.can-13-2690.Search in Google Scholar

102. Wang, J, Sanmamed, MF, Datar, I, Su, TT, Ji, L, Sun, J, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell 2019;176:334–47.e12. https://doi.org/10.1016/j.cell.2018.11.010.Search in Google Scholar PubMed PubMed Central

103. Miyazaki, T, Dierich, A, Benoist, C, Mathis, D. Independent modes of natural killing distinguished in mice lacking Lag3. Science 1996;272:405–8. https://doi.org/10.1126/science.272.5260.405.Search in Google Scholar

104. Huard, B, Tournier, M, Triebel, F. LAG-3 does not define a specific mode of natural killing in human. Immunol Lett 1998;61:109–12. https://doi.org/10.1016/s0165-2478(97)00170-3.Search in Google Scholar

105. Andrews, LP, Marciscano, AE, Drake, CG, Vignali, DAA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 2017;276:80–96. https://doi.org/10.1111/imr.12519.Search in Google Scholar PubMed PubMed Central

106. Zhang, J, Basher, F, Wu, JD. NKG2D ligands in tumor immunity: two sides of a coin. Front Immunol 2015;6. https://doi.org/10.3389/fimmu.2015.00097.Search in Google Scholar PubMed PubMed Central

107. Bastid, J, Regairaz, A, Bonnefoy, N, Dejou, C, Giustiniani, J, Laheurte, C, et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res 2015;3:254–65. https://doi.org/10.1158/2326-6066.cir-14-0018.Search in Google Scholar PubMed

108. Raskovalova, T, Huang, X, Sitkovsky, M, Zacharia, LC, Jackson, EK, Gorelik, E. Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol 2005;175:4383–91. https://doi.org/10.4049/jimmunol.175.7.4383.Search in Google Scholar PubMed

109. Allard, B, Longhi, MS, Robson, SC, Stagg, J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev 2017;276:121–44. https://doi.org/10.1111/imr.12528.Search in Google Scholar PubMed PubMed Central

110. Häusler, SF, del Barrio, IM, Diessner, J, Stein, RG, Strohschein, J, Hönig, A, et al. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am J Transl Res 2014;6:129.Search in Google Scholar

111. Seidel, UJE, Schlegel, P, Lang, P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 2013;4. https://doi.org/10.3389/fimmu.2013.00076.Search in Google Scholar PubMed PubMed Central

112. Bartkowiak, T, Curran, MA. 4-1BB agonists: multi-potent potentiators of tumor immunity. Front Oncol 2015;5. https://doi.org/10.3389/fonc.2015.00117.Search in Google Scholar PubMed PubMed Central

113. Baessler, T, Charton, JE, Schmiedel, BJ, Grünebach, F, Krusch, M, Wacker, A, et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010;115:3058–69. https://doi.org/10.1182/blood-2009-06-227934.Search in Google Scholar PubMed

114. Diefenbach, A, Jensen, ER, Jamieson, AM, Raulet, DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001;413:165–71. https://doi.org/10.1038/35093109.Search in Google Scholar PubMed PubMed Central

115. Holliger, P, Hudson, PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23:1126–36. https://doi.org/10.1038/nbt1142.Search in Google Scholar PubMed

116. Vallera, DA, Zhang, B, Gleason, MK, Oh, S, Weiner, LM, Kaufman, DS, et al. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother Radiopharm 2013;28:274–82. https://doi.org/10.1089/cbr.2012.1329.Search in Google Scholar PubMed PubMed Central

117. Reiners, KS, Kessler, J, Sauer, M, Rothe, A, Hansen, HP, Reusch, U, et al. Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther 2013;21:895–903. https://doi.org/10.1038/mt.2013.14.Search in Google Scholar PubMed PubMed Central

118. JU, Schmohl, Gleason, MK, Dougherty, PR, Miller, JS, Vallera, DA. Heterodimeric bispecific single chain variable fragments (scFv) killer engagers (BiKEs) enhance NK-cell activity against CD133+ colorectal cancer cells. Target Oncol 2016;11:353–61. https://doi.org/10.1007/s11523-015-0391-8.Search in Google Scholar PubMed PubMed Central

119. Reusch, U, Burkhardt, C, Fucek, I, Le Gall, F, Le Gall, M, Hoffmann, K, et al. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs 2014;6:728–39. https://doi.org/10.4161/mabs.28591.Search in Google Scholar PubMed PubMed Central

120. Gleason, MK, Ross, JA, Warlick, ED, Lund, TC, Verneris, MR, Wiernik, A, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 2014;123:3016–26. https://doi.org/10.1182/blood-2013-10-533398.Search in Google Scholar PubMed PubMed Central

121. Turini, M, Chames, P, Bruhns, P, Baty, D, Kerfelec, B. A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy. Oncotarget 2014;5:5304–19. https://doi.org/10.18632/oncotarget.2093.Search in Google Scholar PubMed PubMed Central

122. Dong, B, Zhou, C, He, P, Li, J, Chen, S, Miao, J, et al. A novel bispecific antibody, BiSS, with potent anti-cancer activities. Cancer Biol Ther 2016;17:364–70. https://doi.org/10.1080/15384047.2016.1139266.Search in Google Scholar PubMed PubMed Central

123. Osaki, T, Fujisawa, S, Kitaguchi, M, Kitamura, M, Nakanishi, T. Development of a bispecific antibody tetramerized through hetero-associating peptides. FEBS J 2015;282:4389–401. https://doi.org/10.1111/febs.13505.Search in Google Scholar PubMed

124. Wiernik, A, Foley, B, Zhang, B, Verneris, MR, Warlick, E, Gleason, MK, et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16x33 bispecific killer cell engager and ADAM17 inhibition. Clin Canc Res 2013;19:3844–55. https://doi.org/10.1158/1078-0432.ccr-13-0505.Search in Google Scholar

125. Rothe, A, Sasse, S, Topp, MS, Eichenauer, DA, Hummel, H, Reiners, KS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 2015;125:4024–31. https://doi.org/10.1182/blood-2014-12-614636.Search in Google Scholar PubMed PubMed Central

126. JU, Schmohl, Felices, M, Taras, E, Miller, JS, Vallera, DA. Enhanced ADCC and NK cell activation of an anticarcinoma bispecific antibody by genetic insertion of a modified IL-15 cross-linker. Mol Ther 2016;24:1312–22. https://doi.org/10.1038/mt.2016.88.Search in Google Scholar PubMed PubMed Central

127. JU, Schmohl, Felices, M, Todhunter, D, Taras, E, Miller, JS, Vallera, DA. Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker. Oncotarget 2016;7:73830–44. https://doi.org/10.18632/oncotarget.12073.Search in Google Scholar PubMed PubMed Central

128. Wang, T, Sun, F, Xie, W, Tang, M, He, H, Jia, X, et al. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma. Canc Lett 2016;372:166–78. https://doi.org/10.1016/j.canlet.2016.01.001.Search in Google Scholar PubMed

129. Rothe, A, Jachimowicz, RD, Borchmann, S, Madlener, M, Keßler, J, Reiners, KS, et al. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Int J Canc 2014;134:2829–40. https://doi.org/10.1002/ijc.28609.Search in Google Scholar PubMed

130. Peipp, M, Derer, S, Lohse, S, Staudinger, M, Klausz, K, Valerius, T, et al. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibodydependent cell-mediated cytotoxicity. Oncotarget 2015;6:32075–88. https://doi.org/10.18632/oncotarget.5135.Search in Google Scholar PubMed PubMed Central

131. Xia, Y, Chen, B, Shao, X, Xiao, W, Qian, L, Ding, Y, et al. Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice. J Immunother 2014;37:257–66. https://doi.org/10.1097/cji.0000000000000033.Search in Google Scholar

132. Chen, Y, Chen, B, Yang, T, Xiao, W, Qian, L, Ding, Y, et al. Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells. Cell Mol Immunol 2017;14:293–307. https://doi.org/10.1038/cmi.2015.81.Search in Google Scholar PubMed PubMed Central

133. Vego, H, Sand, KL, Høglund, RA, Fallang, LE, Gundersen, G, Holmøy, T, et al. Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a. Cell Mol Immunol 2016;13:57–64. https://doi.org/10.1038/cmi.2014.114.Search in Google Scholar PubMed PubMed Central

134. Felices, M, Chu, S, Kodal, B, Bendzick, L, Ryan, C, Lenvik, AJ, et al. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. Gynecol Oncol 2017;145:453–61. https://doi.org/10.1016/j.ygyno.2017.02.028.Search in Google Scholar PubMed PubMed Central

135. Rosenberg, SA, Lotze, MT, Muul, LM, Leitman, S, Chang, AE, Ettinghausen, SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485–92. https://doi.org/10.1056/nejm198512053132327.Search in Google Scholar PubMed

136. Malek, TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 2003;74:961–5. https://doi.org/10.1189/jlb.0603272.Search in Google Scholar PubMed

137. Cheng, M, Chen, Y, Xiao, W, Sun, R, Tian, Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013;10:230–52. https://doi.org/10.1038/cmi.2013.10.Search in Google Scholar PubMed PubMed Central

138. Fujisaki, H, Kakuda, H, Shimasaki, N, Imai, C, Ma, J, Lockey, T, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009;69:4010–7. https://doi.org/10.1158/0008-5472.can-08-3712.Search in Google Scholar PubMed PubMed Central

139. Masuyama, J ichi, Murakami, T, Iwamoto, S, Fujita, S. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies. Cytotherapy 2016;18:80–90. https://doi.org/10.1016/j.jcyt.2015.09.011.Search in Google Scholar PubMed

140. Miller, JS, Soignier, Y, Panoskaltsis-Mortari, A, McNearney, SA, Yun, GH, Fautsch, SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051–7. https://doi.org/10.1182/blood-2004-07-2974.Search in Google Scholar PubMed

141. Romanski, A, Uherek, C, Bug, G, Seifried, E, Klingemann, H, Wels, WS, et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med 2016;20:1287–94. https://doi.org/10.1111/jcmm.12810.Search in Google Scholar PubMed PubMed Central

142. Müller, T, Uherek, C, Maki, G, Chow, KU, Schimpf, A, Klingemann, HG, et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 2008;57:411–23. https://doi.org/10.1007/s00262-007-0383-3.Search in Google Scholar PubMed

143. Jiang, H, Zhang, W, Shang, P, Zhang, H, Fu, W, Ye, F, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol 2014;8:297–310. https://doi.org/10.1016/j.molonc.2013.12.001.Search in Google Scholar PubMed PubMed Central

144. Esser, R, Müller, T, Stefes, D, Kloess, S, Seidel, D, Gillies, SD, et al. NK cells engineered to express a GD 2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med 2012;16:569–81. https://doi.org/10.1111/j.1582-4934.2011.01343.x.Search in Google Scholar PubMed PubMed Central

145. Han, J, Chu, J, Keung Chan, W, Zhang, J, Wang, Y, Cohen, JB, et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci Rep 2015;5. https://doi.org/10.1038/srep11483.Search in Google Scholar PubMed PubMed Central

146. Schönfeld, K, Sahm, C, Zhang, C, Naundorf, S, Brendel, C, Odendahl, M, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther 2015;23:330–8. https://doi.org/10.1038/mt.2014.219.Search in Google Scholar PubMed PubMed Central

147. Schirrmann, T, Pecher, G. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. Cancer Gene Ther 2002;9:390–8. https://doi.org/10.1038/sj.cgt.7700453.Search in Google Scholar PubMed

148. Schirrmann, T, Pecher, G. Specific targeting of CD33+ leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk Res 2005;29:301–6. https://doi.org/10.1016/j.leukres.2004.07.005.Search in Google Scholar PubMed

149. Morvan, MG, Lanier, LL. NK cells and cancer: you can teach innate cells new tricks. Nature Reviews Cancer. Nat Rev Cancer 2016;16:7–19. https://doi.org/10.1038/nrc.2015.5.Search in Google Scholar PubMed

150. Aitken, AS, Roy, DG, Bourgeois-Daigneault, MC. Taking a stab at cancer; Oncolytic virus-mediated anti-cancer vaccination strategies. Biomed MDPI AG 2017;5. https://doi.org/10.3390/biomedicines5010003.Search in Google Scholar PubMed PubMed Central

151. Andtbacka, RHI, Kaufman, HL, Collichio, F, Amatruda, T, Senzer, N, Chesney, J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015;33:2780–8. https://doi.org/10.1200/jco.2014.58.3377.Search in Google Scholar

152. Hodgins, JJ, Khan, ST, Park, MM, Auer, RC, Ardolino, M. Killers 2.0: NK cell therapies at the forefront of cancer control. J Clin Invest Am Soc Clin Invest 2019;129:3499–510. https://doi.org/10.1172/jci129338.Search in Google Scholar

153. Chesney, J, Puzanov, I, Collichio, F, Singh, P, Milhem, MM, Glaspy, J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol 2018;36:1658–67. https://doi.org/10.1200/jco.2017.73.7379.Search in Google Scholar PubMed PubMed Central

154. Bhat, R, Dempe, S, Dinsart, C, Rommelaere, J. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int J Cancer 2011;128:908–19. https://doi.org/10.1002/ijc.25415.Search in Google Scholar PubMed

155. Bhat, R, Rommelaere, J. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells. BMC Cancer 2013:13. https://doi.org/10.1186/1471-2407-13-367.Search in Google Scholar PubMed PubMed Central

156. Errington, F, Steele, L, Prestwich, R, Harrington, KJ, Pandha, HS, Vidal, L, et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008;180:6018–26. https://doi.org/10.4049/jimmunol.180.9.6018.Search in Google Scholar PubMed

157. Boudreau, JE, Bridle, BW, Stephenson, KB, Jenkins, KM, Brunellière, J, Bramson, JL, et al. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther 2009;17:1465–72. https://doi.org/10.1038/mt.2009.95.Search in Google Scholar PubMed PubMed Central

158. Lapteva, N, Aldrich, M, Weksberg, D, Rollins, L, Goltsova, T, Chen, SY, et al. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother 2009;32:145–56. https://doi.org/10.1097/cji.0b013e318193d31e.Search in Google Scholar PubMed PubMed Central

159. Stephenson, KB, Barra, NG, Davies, E, Ashkar, AA, Lichty, BD. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther 2012;19:238–46. https://doi.org/10.1038/cgt.2011.81.Search in Google Scholar PubMed

160. Choi, KJ, Zhang, SN, Choi, IK, Kim, JS, Yun, CO. Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF. Gene Ther 2012;19:711–23. https://doi.org/10.1038/gt.2011.125.Search in Google Scholar PubMed

161. Alkayyal, AA, Tai, L-H, Kennedy, MA, de Souza, CT, Zhang, J, Lefebvre, C, et al. NK-cell recruitment is necessary for eradication of peritoneal carcinomatosis with an IL12-expressing Maraba virus cellular vaccine. Cancer Immunol Res 2017;5:211–21. https://doi.org/10.1158/2326-6066.cir-16-0162.Search in Google Scholar

162. Chen, X, Han, J, Chu, J, Zhang, L, Zhang, J, Chen, C, et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget 2016;7:27764–77. https://doi.org/10.18632/oncotarget.8526.Search in Google Scholar PubMed PubMed Central

163. Anfray, C, Aldo, U, Andón, FT, Allavena, P. Current strategies to target tumor-associated-macrophages to improve anti-tumor immune responses. Cells 2019;9:46. https://doi.org/10.3390/cells9010046.Search in Google Scholar PubMed PubMed Central

164. Canè, S, Ugel, S, Trovato, R, Marigo, I, De Sanctis, F, Sartoris, S, et al. The endless saga of monocyte diversity. Front Immunol 2019;10:1786. https://doi.org/10.3389/fimmu.2019.01786.Search in Google Scholar PubMed PubMed Central

165. Liu, L, He, H, Liang, R, Yi, H, Meng, X, Chen, Z, et al. ROS-inducing Micelles sensitize tumor-associated macrophages to TLR3 stimulation for potent immunotherapy. Biomacromolecules 2018;19:2146–55. https://doi.org/10.1021/acs.biomac.8b00239.Search in Google Scholar PubMed

166. Zhao, J, Zhang, Z, Xue, Y, Wang, G, Cheng, Y, Pan, Y, et al. Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I : C) promote melanoma regression. Theranostics 2018;8:6307–21. https://doi.org/10.7150/thno.29746.Search in Google Scholar PubMed PubMed Central

167. Perkins, H, Khodai, T, Mechiche, H, Colman, P, Burden, F, Laxton, C, et al. Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model. J Clin Immunol 2012;32:1082–92. https://doi.org/10.1007/s10875-012-9687-y.Search in Google Scholar PubMed

168. Haabeth, OAW, Blake, TR, McKinlay, CJ, Tveita, AA, Sallets, A, Waymouth, RM, et al. Local delivery of Ox40l, Cd80, and Cd86 mRNA kindles global anticancer immunity. Cancer Res 2019;79:1624–34. https://doi.org/10.1158/0008-5472.can-18-2867.Search in Google Scholar

169. Zhang, F, Parayath, NN, Ene, CI, Stephan, SB, Koehne, AL, Coon, ME, et al. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat Commun 2019;10:3974. https://doi.org/10.1038/s41467-019-11911-5.Search in Google Scholar PubMed PubMed Central

170. Song, Y, Tang, C, Yin, C. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells. Biomaterials 2018;185:117–32. https://doi.org/10.1016/j.biomaterials.2018.09.017.Search in Google Scholar PubMed

171. Zang, X, Zhang, X, Hu, H, Qiao, M, Zhao, X, Deng, Y, et al. Targeted delivery of zoledronate to tumor-associated macrophages for cancer immunotherapy. Mol Pharm 2019;16:2249–58. https://doi.org/10.1021/acs.molpharmaceut.9b00261.Search in Google Scholar PubMed

172. Yang, H, Shao, R, Huang, H, Wang, X, Rong, Z, Lin, Y. Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis. Cancer Med 2019;8:4245–53. https://doi.org/10.1002/cam4.2461.Search in Google Scholar

173. Advani, R, Flinn, I, Popplewell, L, Forero, A, Bartlett, NL, Ghosh, N, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med 2018;379:1711–21. https://doi.org/10.1056/nejmoa1807315.Search in Google Scholar

174. Beatty, GL, Chiorean, EG, Fishman, MP, Saboury, B, Teitelbaum, UR, Sun, W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612–6. https://doi.org/10.1126/science.1198443.Search in Google Scholar PubMed PubMed Central

175. Vonderheide, RH. CD40 agonist antibodies in cancer immunotherapy. Annu Rev Med 2020;71:47–58. https://doi.org/10.1146/annurev-med-062518-045435.Search in Google Scholar PubMed

176. Sabado, RL, Balan, S, Bhardwaj, N. Dendritic cell-based immunotherapy. Cell Res 2017;27:74–95. https://doi.org/10.1038/cr.2016.157.Search in Google Scholar PubMed PubMed Central

177. Rini, B. Future approaches in immunotherapy. Semin Oncol 2014;41:S30–40. https://doi.org/10.1053/j.seminoncol.2014.09.005.Search in Google Scholar PubMed

178. Wolchok, JD, Hoos, A, O’Day, S, Weber, JS, Hamid, O, Lebbé, C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Canc Res 2009;15:7412–20. https://doi.org/10.1158/1078-0432.ccr-09-1624.Search in Google Scholar PubMed

179. Anguille, S, Smits, EL, Bryant, C, Van Acker, HH, Goossens, H, Lion, E, et al. Dendritic cells as pharmacological tools for cancer immunotherapys. Pharmacol Rev 2015;67:731–53. https://doi.org/10.1124/pr.114.009456.Search in Google Scholar PubMed

180. Galluzzi, L, Senovilla, L, Vacchelli, E, Eggermont, A, Fridman, WH, Galon, J, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012;1:1111–34. https://doi.org/10.4161/onci.21494.Search in Google Scholar PubMed PubMed Central

181. Palucka, K, Banchereau, J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12:265–77. https://doi.org/10.1038/nrc3258.Search in Google Scholar PubMed PubMed Central

182. Pizzurro, GA, Barrio, MM. Dendritic cell-based vaccine efficacy: aiming for hot spots. Front Immunol 2015;6:91. https://doi.org/10.3389/fimmu.2015.00091.Search in Google Scholar PubMed PubMed Central

183. Bol, KF, Schreibelt, G, Gerritsen, WR, de Vries, IJM, Figdor, CG. Dendritic cell-based immunotherapy: state of the art and beyond. Clin Canc Res 2016;22:1897–906. https://doi.org/10.1158/1078-0432.ccr-15-1399.Search in Google Scholar

184. Constantino, J, Gomes, C, Falcão, A, Cruz, MT, Neves, BM. Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. Transl Res 2016;168:74–95. https://doi.org/10.1016/j.trsl.2015.07.008.Search in Google Scholar PubMed

185. Galluzzi, L, Vacchelli, E, Bravo-San Pedro, JM, Buqué, A, Senovilla, L, Baracco, EE, et al. Classification of current anticancer immunotherapies. Oncotarget 2014;5:12472–508. https://doi.org/10.18632/oncotarget.2998.Search in Google Scholar PubMed PubMed Central

186. Timmerman, JM, Levy, R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999;50:507–29. https://doi.org/10.1146/annurev.med.50.1.507.Search in Google Scholar PubMed

187. Kantoff, PW, Higano, CS, Shore, ND, Berger, ER, Small, EJ, Penson, DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411–22. https://doi.org/10.1056/nejmoa1001294.Search in Google Scholar

188. Scholz, M, Yep, S, Chancey, M, Kelly, C, Chau, K, Turner, J, et al. Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer. ImmunoTargets Ther 2017;6:11–6. https://doi.org/10.2147/itt.s122497.Search in Google Scholar PubMed PubMed Central

189. Urbanova, L, Hradilova, N, Moserova, I, Vosahlikova, S, Sadilkova, L, Hensler, M, et al. High hydrostatic pressure affects antigenic pool in tumor cells: implication for dendritic cell-based cancer immunotherapy. Immunol Lett 2017;187:27–34. https://doi.org/10.1016/j.imlet.2017.05.005.Search in Google Scholar PubMed

190. Hradilova, N, Sadilkova, L, Palata, O, Mysikova, D, Mrazkova, H, Lischke, R, et al. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy, Shiku H, editor. PloS ONE 2017;12:e0171539. https://doi.org/10.1016/j.jtho.2017.11.079.Search in Google Scholar

191. Podrazil, M, Horvath, R, Becht, E, Rozkova, D, Bilkova, P, Sochorova, K, et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget 2015;6:18192–205. https://doi.org/10.18632/oncotarget.4145.Search in Google Scholar PubMed PubMed Central

192. Steinman, RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012;30:1–22. https://doi.org/10.1146/annurev-immunol-100311-102839.Search in Google Scholar PubMed

193. Tacken, PJ, Figdor, CG. Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines. Semin Immunol 2011;23:12–20. https://doi.org/10.1016/j.smim.2011.01.001.Search in Google Scholar PubMed

194. Hawiger, D, Inaba, K, Dorsett, Y, Guo, M, Mahnke, K, Rivera, M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001;194:769–79. https://doi.org/10.1084/jem.194.6.769.Search in Google Scholar PubMed PubMed Central

195. Bonifaz, L, Bonnyay, D, Mahnke, K, Rivera, M, Nussenzweig, MC, Steinman, RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002;196:1627–38. https://doi.org/10.1084/jem.20021598.Search in Google Scholar PubMed PubMed Central

196. Palucka, K, Banchereau, J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013;39:38–48. https://doi.org/10.1016/j.immuni.2013.07.004.Search in Google Scholar PubMed PubMed Central

197. Bonifaz, LC, Bonnyay, DP, Charalambous, A, Darguste, DI, Fujii, SI, Soares, H, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004;199:815–24. https://doi.org/10.1084/jem.20032220.Search in Google Scholar PubMed PubMed Central

198. Caminschi, I, Maraskovsky, E, Heath, WR. Targeting dendritic cells in vivo for cancer therapy. Front Immunol 2012;3:13. https://doi.org/10.3389/fimmu.2012.00013.Search in Google Scholar PubMed PubMed Central

199. Hartung, E, Becker, M, Bachem, A, Reeg, N, Jäkel, A, Hutloff, A, et al. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1. J Immunol 2015;194:1069–79. https://doi.org/10.4049/jimmunol.1401903.Search in Google Scholar PubMed

200. Terhorst, D, Fossum, E, Baranska, A, Tamoutounour, S, Malosse, C, Garbani, M, et al. Laser-assisted intradermal delivery of adjuvant-free vaccines targeting XCR1 + dendritic cells induces potent antitumoral responses. J Immunol 2015;194:5895–902. https://doi.org/10.4049/jimmunol.1500564.Search in Google Scholar PubMed

201. Fossum, E, Grødeland, G, Terhorst, D, Tveita, AA, Vikse, E, Mjaaland, S, et al. Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus. Eur J Immunol 2015;45:624–35. https://doi.org/10.1002/eji.201445080.Search in Google Scholar PubMed